The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
Endocrine Cancer
ENDOCRINE CANCER ADVISOR
FEATURED CONTENT
-
-
How Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators. -
Reporting Mechanisms for Conflict of Interest Disclosures in Medicine Need Standardization
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system. -
Popular Genetic Tests Miss Many Cancer-Associated Genetic Variants, Particularly in Ethnic Minorities
The chance of missing a disease-causing variant can be as high as 100% across some groups. -
When Patient-Reported Outcomes Could Pose Risks
During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.
ENDOCRINE CANCER NEWS
No Link Found Between Hepatitis C Infection and Extrahepatic Cancers
Pediatric Thyroid Cancer Rates Are Rising, but Some Experts Doubt the Significance
Factors Associated With Thyroid Cancer Overtreatment Identified
Radiation From CT Scans Linked to Thyroid Cancer, Leukemia
Practice Setting Linked to Receipt of More Costly Cancer Drugs
Want to read more?
Please login or register first to view this content.
Next post in Endocrine Cancer
